Last 12 months
Inside the activity.
6 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 6 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 21:05 UTC |
Mahatme UjwalaDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.82 | Not disclosed |
DisclosureSEC source: 0001599298-22-000007 · wf-form4_164141670774490.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 16:09 UTC |
Maranian Jeffrey RVP Corporate Controller
|
GrantStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001871604-21-000004 · wf-form4_163977535437475.xml · derivative · entry 1 Maranian Jeffrey R · CIK 0001871604 · VP Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-12-15 F2 · price: (2) Not applicable. F1 · derivative.exercise_date: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date). Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:16 UTC |
Zanganeh MahkamDirector · Chief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001599298-21-000039 · wf-form4_163977578709580.xml · derivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-12-15 F2 · price: (2) Not applicable. F1 · derivative.exercise_date: (1) The option was granted on December 15, 2021. The shares underlying the option are scheduled to vest on December 15, 2024 (the three-year anniversary of the grant date). Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:19 UTC |
Maranian Jeffrey RVP Corporate Controller
|
GrantStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $5.28 | Not disclosed |
DisclosureSEC source: 0001871604-21-000002 · wf-form4_163701118201148.xml · derivative · entry 1 Maranian Jeffrey R · CIK 0001871604 · VP Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-11-11 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on November 11, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 11, 2022. Read SEC document |
| November 03, 2021 Filed Nov 16, 2021 17:17 UTC |
Gayko UrteDirector
|
GrantStock Option (right to buy) · Derivative | 4,041 | Not disclosed Strike: $5.54 | Not disclosed |
DisclosureSEC source: 0000921895-21-002700 · form412566001_11162021.xml · derivative · entry 2 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,041 Underlying: Common Stock · 4,041 shares Expires 2031-11-03 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on November 3, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| November 03, 2021 Filed Nov 16, 2021 17:17 UTC |
Gayko UrteDirector
|
GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $5.54 | Not disclosed |
DisclosureSEC source: 0000921895-21-002700 · form412566001_11162021.xml · derivative · entry 1 Gayko Urte · CIK 0001559217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-11-03 F3 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on November 3, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 3, 2022. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 08:40 UTC |
Clark Kenneth ADirector
|
GrantStock Option (right to buy) · Derivative | 6,250 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0000921895-21-002408 · form412566003_10112021.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 6,250 shares Expires 2031-10-07 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on October 7, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 08:40 UTC |
Clark Kenneth ADirector
|
GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0000921895-21-002408 · form412566003_10112021.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-10-07 F3 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on October 7, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 7, 2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:39 UTC |
DUGGAN ROBERT WDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 11,365,921 | $5.24 | $59,557,426.04 |
DisclosureSEC source: 0000921895-21-001335 · form412566dug_05142021.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,662,454 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:37 UTC |
Zanganeh MahkamDirector · Chief Operating Officer
|
PurchaseCommon Stock | 389,077 | $5.24 | $2,038,763.48 |
DisclosureSEC source: 0000921895-21-001334 · form412566zan_05142021.xml · nonDerivative · entry 1 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee. Disclosed balance after: 2,643,319 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 22:36 UTC |
Wang LuhuaDirector
|
GrantStock Option (right to buy) · Derivative | 21,096 | $6.77 Strike: $6.77 | $142,819.92 |
DisclosureSEC source: 0000921895-21-000601 · form412566002_03022021.xml · derivative · entry 2 Wang Luhua · CIK 0001847910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,096 Underlying: Common Stock · 21,096 shares Expires 2031-02-28 F2 · derivative.exercise_date: The option was granted on February 28, 2021 and represents a pro rata amount of the annual 25,000 option board grant based on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:36 UTC |
Wang LuhuaDirector
|
GrantStock Option (right to buy) · Derivative | 70,000 | $6.77 Strike: $6.77 | $473,900.00 |
DisclosureSEC source: 0000921895-21-000601 · form412566002_03022021.xml · derivative · entry 1 Wang Luhua · CIK 0001847910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-02-26 F1 · derivative.exercise_date: The option was granted on February 26, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on February 26, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:01 UTC |
Erdtmann Rainer MDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0000921895-21-000544 · form412566erd_02232021.xml · derivative · entry 1 Erdtmann Rainer M · CIK 0001455767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,273 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:04 UTC |
Soni Manmeet SinghDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0000921895-21-000545 · form412566sin_02232021.xml · derivative · entry 1 Soni Manmeet Singh · CIK 0001569769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,273 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:59 UTC |
Donaldson Michael PaulChief Financial Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 5,110 | Not disclosed Strike: $3.52 | Not disclosed |
DisclosureSEC source: 0000921895-21-000543 · form412566don_02232021.xml · derivative · entry 1 Donaldson Michael Paul · CIK 0001824022 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,890 Underlying: Common Stock · 5,110 shares Expires 2030-06-08 F1 · shares: Represents the forfeiture of performance-based stock options granted to the Reporting Person on June 8, 2020 that were eligible to vest based on certain performance conditions. Upon grant, the target vesting amount was reported in Table II of Form 3. On February 19, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that, based on the Issuer's performance over the applicable performance period, 37,129 shares would vest and 5,110 shares would be forfeited. F3 · price: Not applicable. F2 · derivative.exercise_date: As of February 19, 2021, a total of 79,368 shares have vested and 515,522 shares remain eligible to vest from this grant. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:55 UTC |
Mahatme UjwalaDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0000921895-21-000542 · form412566uja_02232021.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,340 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 13,713 | $1.79 Strike: $1.79 | $24,546.27 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 8 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,973 Underlying: Common Stock · 13,713 shares Expires 2029-03-29 F5 · derivative.exercise_date: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
SaleCommon Stock | 13,713 | $4.44 | $60,885.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 5 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.50. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 13,713 | $1.79 | $24,546.27 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 4 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 12,953 | $1.79 Strike: $1.79 | $23,185.87 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 7 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,686 Underlying: Common Stock · 12,953 shares Expires 2029-03-29 F5 · derivative.exercise_date: The option was granted on March 29, 2019. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 16,616 | $1.92 Strike: $1.92 | $31,902.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · derivative · entry 6 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,639 Underlying: Common Stock · 16,616 shares Expires 2028-10-19 F4 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
SaleCommon Stock | 29,569 | $4.39 | $129,807.91 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 3 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.30 to $4.66. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 12,953 | $1.79 | $23,185.87 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 2 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:45 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 16,616 | $1.92 | $31,902.72 |
DisclosureSEC source: 0000921895-20-003153 · form412566003_12012020.xml · nonDerivative · entry 1 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 12,070 | $1.92 Strike: $1.92 | $23,174.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 9 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,255 Underlying: Common Stock · 12,070 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
SaleCommon Stock | 12,070 | $4.32 | $52,142.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 6 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.40 to $4.21. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 12,070 | $1.92 | $23,174.40 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 5 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 11,374 | $1.92 Strike: $1.92 | $21,838.08 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 8 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,325 Underlying: Common Stock · 11,374 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
SaleCommon Stock | 11,374 | $4.21 | $47,884.54 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 4 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.24 to $4.20. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 11,374 | $1.92 | $21,838.08 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 3 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
OtherStock Option (right to buy) · Derivative | 6,987 | $1.92 Strike: $1.92 | $13,415.04 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · derivative · entry 7 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,699 Underlying: Common Stock · 6,987 shares Expires 2028-10-19 F5 · derivative.exercise_date: The option was granted on October 19, 2018. The shares underlying the option are scheduled to vest quarterly after the first anniversary of the grant date, on the basis of 11.11% per quarter, with the final shares vesting on the third anniversary of the grant date. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
SaleCommon Stock | 6,987 | $4.40 | $30,742.80 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 2 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price for this entry in column 4 is a weighted average. The price per share actually received ranged from $4.41 to $4.40. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:51 UTC |
Powell David JonathanChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,987 | $1.92 | $13,415.04 |
DisclosureSEC source: 0001193805-20-001473 · e620105_4-powell.xml · nonDerivative · entry 1 Powell David Jonathan · CIK 0001824493 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock received by the Reporting Person as a result of the exercise of stock options set forth in Table II, which shares were subsequently sold in the open market at prevailing market prices. Read SEC document |
| November 22, 2020 Filed Nov 24, 2020 23:12 UTC |
Zanganeh MahkamDirector · Chief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 2,400,000 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0000921895-20-003108 · form412566zan_11242020.xml · derivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724,499 Underlying: Common Stock · 2,400,000 shares Expires 2030-11-22 F1 · price: The option was granted on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 22, 2021, subject to the satisfaction of certain performance targets. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:25 UTC |
Zanganeh MahkamDirector
|
GrantStock Option (right to buy) · Derivative | 3,323 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0000921895-20-002948 · form412566001_11132020.xml · derivative · entry 4 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,500 Underlying: Common Stock · 3,323 shares Expires 2030-11-11 F2 · price: The option was granted on November 11, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in full on December 31, 2020. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:25 UTC |
Zanganeh MahkamDirector
|
GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $3.71 | Not disclosed |
DisclosureSEC source: 0000921895-20-002948 · form412566001_11132020.xml · derivative · entry 3 Zanganeh Maky · CIK 0001507650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,177 Underlying: Common Stock · 200,000 shares Expires 2030-11-11 F1 · price: The option was granted on November 11, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 11, 2021. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:25 UTC |
DUGGAN ROBERT WDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 14,071,856 | $3.34 | $46,999,999.04 |
DisclosureSEC source: 0000921895-20-002868 · form412566001_11102020.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,296,533 F1 · shares: Represents the number of shares of Common Stock that the Reporting Person purchased in a private placement at a price of $3.34 per share pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). Pursuant to the Purchase Agreement, the Issuer directed the Reporting Person to purchase 14,071,856 shares of Common Stock. Read SEC document |
| October 04, 2020 Filed Oct 7, 2020 23:47 UTC |
Graham CamillaChief Clinical Affairs Officer
|
GrantStock Option (right to buy) · Derivative | 400,000 | $3.34 Strike: $3.34 | $1,336,000.00 |
DisclosureSEC source: 0000921895-20-002557 · form412566002_10072020.xml · derivative · entry 1 Graham Camilla · CIK 0001827543 · Chief Clinical Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-10-04 F1 · derivative.exercise_date: The option was granted on October 4, 2020 pursuant to the Company's 2020 Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 4, 2021, subject to the satisfaction of certain performance targets. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 23:42 UTC |
DUGGAN ROBERT WDirector · Chief Executive Officer · 10% owner
|
GrantCommon Stock · Derivative | 9,730,539 | Not disclosed Strike: $3.34 | Not disclosed |
DisclosureSEC source: 0000921895-20-002547 · form412566002_10062020.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,730,539 Underlying: Common Stock · 9,730,539 shares Expires not disclosed F1 · shares: Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement. F1 · price: Represents the minimum number of shares that the Reporting Person shall be obligated to purchase in a private placement pursuant to a Securities Purchase Agreement, dated October 2, 2020, by and between the Reporting Person and the Issuer (the "Purchase Agreement"). The Purchase Agreement affords the Issuer sole discretion to place up to 14,970,060 shares of Common Stock or as few as 9,730,539 shares of Common Stock to the Reporting Person. The shares are issuable at price of $3.34 per share of Common Stock in accordance with the terms of the Purchase Agreement. F2 · derivative.exercise_date: The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time. F2 · derivative.expiration_date: The closing of the Purchase Agreement is anticipated to occur in approximately two weeks' time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.